Tag: psychotherapist

Narcissistic Personality Disorder: Two Faces Explained

The key difference between vulnerable narcissistic personality disorder (NPD) and grandiose NPD lies in how the narcissistic traits are expressed and how the person copes with feelings of inadequacy and low self-esteem. Both fall under the umbrella of narcissistic personality disorder, but they represent different presentations:

Grandiose Narcissism

  • Core Traits:
    • Overt self-importance and entitlement.
    • A strong sense of superiority and belief in their own greatness.
    • Craving admiration and validation from others.
    • Often charismatic, confident, and socially dominant.
  • Defense Mechanisms:
    • Rely on denial and externalizing blame to avoid feeling vulnerable.
    • Tend to dismiss or belittle others’ opinions if they conflict with their own.
  • Interpersonal Behavior:
    • Exploitative in relationships, using others to bolster their self-esteem.
    • Seek out positions of power or visibility to maintain their inflated self-image.
  • Emotional Regulation:
    • Typically outwardly composed and unbothered, though they may become aggressive or vindictive if their self-image is challenged.

Vulnerable Narcissism

  • Core Traits:
    • Feelings of inadequacy, hypersensitivity to criticism, and low self-esteem.
    • A covert sense of entitlement—believing they deserve admiration but fearing they won’t get it.
    • A façade of humility or introversion, masking deep insecurities.
  • Defense Mechanisms:
    • Use avoidance and withdrawal to protect themselves from perceived rejection or failure.
    • Internalize blame and self-doubt, leading to cycles of shame and self-criticism.
  • Interpersonal Behavior:
    • Appear shy, reserved, or socially anxious, but they harbor fantasies of being special or recognized.
    • May oscillate between needing reassurance and distancing themselves from others out of fear of being hurt.
  • Emotional Regulation:
    • Prone to depression, anxiety, and mood swings.
    • Vulnerable to feelings of emptiness and envy of others’ success.

Clinical Distinction

  • While grandiose narcissists may seem outwardly self-assured and dominant, vulnerable narcissists are more likely to present with symptoms resembling mood or anxiety disorders, often masking their narcissistic traits.
  • Both types share a fragile self-esteem at their core but manifest it in opposite ways: grandiose types inflate their self-image, while vulnerable types retreat into themselves.

Grandiose Narcissism in a Clinical Setting

Case Example:

  • Presentation: A 45-year-old CEO attends therapy after his spouse threatens divorce, citing his arrogance and lack of empathy. He describes the problem as “Everyone just misunderstands how hard it is to be as driven and successful as me.”
  • Behavior in Session:
    • Dominates conversations, dismisses the therapist’s insights, and subtly challenges their expertise.
    • Boasts about his achievements, financial success, and social status but avoids discussing emotional issues or personal failures.
    • Minimizes his spouse’s complaints as “overreactions,” viewing them as jealous or ungrateful.
  • Underlying Issues:
    • Although he appears self-confident, his grandiosity masks deep fears of failure and inadequacy.
    • His need for admiration and his inability to tolerate criticism create interpersonal conflict.
  • Therapeutic Challenge:
    • Establishing rapport while gently confronting his defensiveness.
    • Helping him acknowledge and address the vulnerability underlying his grandiosity without triggering a withdrawal or rage response.

Vulnerable Narcissism in a Clinical Setting

Case Example:

  • Presentation: A 30-year-old graduate student seeks therapy for persistent depression and social anxiety. She describes herself as “a failure” and avoids academic conferences because she feels “everyone there is smarter and more talented.”
  • Behavior in Session:
    • Initially shy and reserved but gradually reveals fantasies of being recognized as brilliant and exceptional in her field.
    • Complains about colleagues receiving awards, feeling envious and deeply resentful, but also guilty for having those feelings.
    • Struggles to accept praise, dismissing it as insincere or undeserved, and reacts strongly to perceived slights or criticism.
  • Underlying Issues:
    • She feels torn between craving recognition and fearing rejection.
    • Her self-esteem depends heavily on external validation, but she avoids situations where she might fail or be criticized.
  • Therapeutic Challenge:
    • Helping her tolerate and process feelings of inadequacy without retreating into shame or avoidance.
    • Building her sense of self-worth independent of external achievements or comparisons.

Comparison:

  1. Interpersonal Dynamics:
    • Grandiose narcissists demand validation and admiration from others; vulnerable narcissists fear and avoid situations where their insecurities might be exposed.
    • The CEO pressures the therapist to affirm his greatness, while the student fears the therapist will see her as inadequate.
  2. Emotional Reactions:
    • The CEO might react to confrontation with anger or dismissal, while the student might respond with shame or withdrawal.
  3. Defense Mechanisms:
    • Grandiose types externalize blame (“They’re the problem”), whereas vulnerable types internalize it (“I’m the problem”).

Clinical Insights

Both types present challenges in therapy:

  • Grandiose narcissists may struggle with self-reflection, requiring careful, non-confrontational approaches to expose vulnerabilities.
  • Vulnerable narcissists are often more willing to explore their insecurities but may require help managing their intense shame and self-doubt.

0

Breaking Down Barriers: The Impact of Psychotherapy on Suicidal Ideation and Attempts

New Insights from JAMA

This systematic review and meta-analysis dives deep into the impact of both direct and indirect psychotherapy on suicidal ideation and suicide attempts.

Key takeaways:

  1. Broad Scope: The study analyzed a vast array of data, ensuring a comprehensive overview of psychotherapy’s effectiveness in reducing suicidal thoughts and behaviors.
  2. Direct vs. Indirect Therapy: It highlights the distinct impacts of direct (face-to-face) and indirect (telehealth, self-help) psychotherapeutic approaches.
  3. Hope for Patients: The findings are a beacon of hope, showing significant reductions in suicidal ideation and attempts post-therapy.

As healthcare providers, this data reinforces the crucial role of psychotherapy in our therapeutic arsenal. It’s a powerful reminder of how our interventions can save lives and offer patients a brighter, more hopeful future.

For those in psychiatry and mental health care, this is a must-read article that could shape how we approach treatment for individuals at risk.

Let’s continue to break down barriers and provide life-saving care. 💪✨

Link to the article: https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2824096

0

Hoarding Disorder: A Looming National Crisis?

A recent article on Medscape, Hoarding Disorder: A Looming National Crisis?, highlights the growing prevalence of hoarding disorder (HD) among older adults. While HD affects approximately 2% of the general population, studies suggest that prevalence may reach up to 6% among individuals over 70 years old.

HD is characterized by persistent difficulty discarding possessions, even those with little to no monetary value. For individuals with HD, these items often provide a sense of security or serve as emotional reminders of the past. To outsiders, it’s difficult to understand why these possessions hold such deep significance, but for the person with HD, the items have profound sentimental value.

Hoarding disorder is sometimes viewed as a subset of obsessive-compulsive disorder (OCD), but the overlap is not absolute. Many individuals with HD do not meet diagnostic criteria for OCD and often fail to respond to traditional OCD treatments. In my practice, I’ve come to conceptualize HD less as an extension of OCD and more as a personality-related condition influenced by environmental and psychological factors. For instance, many individuals with HD grew up in homes where similar behaviors were modeled. However, the precise causes of HD remain unclear.

The consequences of HD are particularly concerning in older adults. The accumulation of clutter can pose significant safety risks, including fire hazards, tripping injuries, and even the potential for homelessness. These dangers were evident in a recent consult case where a medical team sought a psychiatric assessment of an elderly patient living in a severely cluttered home. Although the risks were undeniable, the individual did not meet criteria for psychiatric hospitalization. Even if hospitalization were an option, there is no FDA-approved treatment for HD at this time.

The most evidence-based intervention we have for HD is cognitive-behavioral therapy (CBT), which requires sustained engagement over many weeks. Unfortunately, a key barrier is that many individuals with HD do not recognize the need for change or are reluctant to participate in therapy. This makes HD a uniquely challenging condition to address.

Effective management of HD begins with education—helping patients understand the disorder, its risks, and the available treatment options. But education alone is not enough. We urgently need robust community support systems, including services to assist with clearing hazardous clutter and providing ongoing support to encourage treatment adherence.

Inpatient psychiatric hospitalization, in my opinion, offers little benefit for HD. Instead, we need long-term, community-focused solutions. While policymakers often call for greater action to address mental health challenges, they frequently overlook the resource constraints faced by frontline providers. If we are to rise to this challenge, funding and systemic support must match the urgency of their rhetoric.

HD is more than a personal struggle—it’s a public health issue with profound implications for individuals, families, and communities. As healthcare providers, we are ready to do more. Now, we need our leaders to step up and provide the resources to make that possible.

0

Cyproheptadine in Anorexia: Appetite Booster or Waste of Time

Over the past few posts, I’ve been using real cases from my practice to highlight essential teaching points in managing complex conditions. Anorexia nervosa, one of the most severe and high-mortality disorders I encounter, demands a multifaceted approach, especially in critical cases. Recently, I had to explore every possible option to support a particularly challenging case, including cyproheptadine—a medication with potential benefits in anorexia. I decided to dive deeper into the evidence supporting its use. At the end of this post, I’ll share my own experience with cyproheptadine in this case and whether it made a difference in the outcome

Cyproheptadine has been studied in the treatment of anorexia, particularly anorexia nervosa, due to its appetite-stimulating and antihistaminic properties. Some early randomized controlled trials (RCTs) suggested it might have benefits, especially for anorexia nervosa with certain subtypes, but the evidence has been mixed, and it’s not widely recommended in current guidelines.

  1. Weight Gain: Cyproheptadine has been shown in some RCTs to help promote weight gain in individuals with anorexia nervosa, particularly in those with a restricting type of the disorder. However, results have not been consistent across studies, with some trials finding minimal or no effect on weight gain.
  2. Symptom Relief: Cyproheptadine may help reduce anxiety and obsessive thoughts related to food, as its antihistaminic and mild sedative effects can have a calming influence. However, this has not been strongly confirmed across all trials.
  3. Limitations and Side Effects: The mixed evidence may relate to differences in study designs, anorexia subtypes studied, and dosages used. Side effects, such as sedation, have also limited its use, especially in outpatient settings where these effects might interfere with daily functioning.

Overall, while some RCTs have shown cyproheptadine might help with weight gain and symptom relief in anorexia, particularly in non-binging types, the evidence remains inconclusive. In my personal practice with the medication, I saw limited if any benefit by adding this medication to current standard of treatment. We are often looking for solutions to complex difficult to treat conditions such as anorexia, but the benefits here seem to be limitted both from the research and clinical perspective. 

0

Setback for MDMA Therapy: FDA’s Rejection and Key Concerns Explained

The FDA’s decision to reject MDMA (methylenedioxymethamphetamine) for medical use typically stems from various concerns related to safety, efficacy, and potential for abuse.

Background

MDMA is primarily known as a recreational drug, often associated with rave and party scenes. However, it has been studied for its potential therapeutic benefits, particularly in the treatment of post-traumatic stress disorder (PTSD) and other mental health conditions.

Safety Concerns

  1. Neurotoxicity: Research has shown that MDMA can be neurotoxic, causing damage to serotonin-producing neurons in the brain. This can lead to long-term cognitive deficits, including memory problems and mood disorders.
  2. Cardiovascular Risks: MDMA increases heart rate and blood pressure, which can pose significant risks to individuals with underlying heart conditions. The stimulant effect can lead to hyperthermia (overheating) and dehydration.
  3. Acute Toxicity: Overdose can lead to severe hyperthermia, serotonin syndrome, and even death. The narrow therapeutic window between a therapeutic dose and a toxic dose is a significant concern.

Efficacy Concerns

  1. Clinical Trial Results: While there have been promising results in some clinical trials, the FDA requires extensive, well-controlled studies to confirm a drug’s efficacy. If trials do not meet these rigorous standards, the FDA may not approve the drug.
  2. Long-term Benefits: The long-term efficacy of MDMA therapy is still uncertain. While short-term benefits have been observed, there is a need for more data on the sustainability of these effects.

Potential for Abuse and Addiction

  1. Recreational Use: MDMA is widely used recreationally, which increases the potential for misuse and addiction. The FDA must consider the risk of the drug being diverted for non-medical use.
  2. Dependence: There is evidence that regular use of MDMA can lead to psychological dependence, and managing this risk is crucial in the context of medical approval.

Regulatory and Ethical Considerations

  1. Ethical Concerns: The use of a psychoactive substance in a therapeutic setting raises ethical questions, particularly regarding informed consent and the management of potential adverse effects.
  2. Regulatory Framework: The FDA has stringent requirements for approving new medications, including ensuring that benefits outweigh risks. For a drug like MDMA, where the risks are significant, the bar for approval is high.

Conclusion

The FDA panel recently rejected the use of MDMA-assisted psychotherapy for treating PTSD, marking a significant setback for advocates of this treatment approach. The advisory committee, in a vote of 9-2, concluded that the current evidence does not support the effectiveness of MDMA in treating PTSD. Additionally, they voted 10-1 against the benefits of MDMA therapy outweighing its risks​. 

Several key concerns led to this decision. Firstly, issues were raised about the integrity and validity of the clinical trials conducted by Lykos Therapeutics, including potential biases, functional unblinding, and allegations of misconduct. The panel also highlighted gaps in the data, particularly regarding the potential for abuse and adverse cardiovascular events associated with MDMA​​.

Despite the panel’s recommendation, the FDA is not obligated to follow their advice, though it often does. The outcome has disappointed many proponents of MDMA-assisted therapy, who argue that the treatment could provide much-needed relief for PTSD patients who have not benefited from existing therapies​. 

0

Psychiatrists Are More Than Just Prescribers

Introduction:

I get a lot of comments that go something like this “All psychiatrists do is prescribe medications.” Naturally, people are shocked when I talk about nutritional psychiatry, lifestyle modification, or the value of psychotherapy. I cover a lot of medication information on social media because there is significant confusion, misinformation, and a general benefit for patients to know more about the medications they routinely use. 

While medication management is a substantial portion of the work most psychiatrists do it’s not the only things we do. 

Psychotherapy: 

Most psychiatrists are well trained in at least one type of psychotherapy. The most common ones include cognitive behavioral therapy, interpersonal therapy, and motivational interviewing. Some are trained extensively in psychoanalysis which usually requires a 5-year commitment and engagement in psychoanalysis as a patient.

Procedures: 

Many psychiatrists offer procedure-based interventions such as electroconvulsive therapy (ECT), and trans cranial magnetic stimulation (TMS). We may also consult on cases of vagus nerve stimulation or deep brain stimulation used to treat severe depression. 

Neurological Disorders: 

As a psychiatrist you are trained to handle some of the common neurological disorders (e.g. migraine). One third of our board examination is focused on neurological disease. In rural parts of the United States sometimes there is no one else to treat these disorders and the responsibility falls to psychiatry. 

Medical Disorders: 

Most psychiatrists can treat things like hypertension or hypothyroidism. Many make the choice not to if the patient has a primary care physician. Like the treatment of neurological disorders sometimes there is no choice, and a psychiatrist will need to treat the medical condition. 

Social Work: 

Not everyone is lucky enough to have designated social workers so they can focus exclusively on the treatment of patients. We all know how important social determinates of mental health are, and sometimes altering these circumstances is the responsibility of the psychiatrist. 

0

Powered by WordPress.com.

Up ↑